We are proud to announce the first POC data achieved in advanced preclinical models with our personalized vaccine platform based on NeoAntigen Identification/DNA Electroporation and published on Journal of Experimental & Clinical Cancer Research.
We have developed different neoantigen minigene vaccine vectors to determine the rules for a successful neoantigen cancer vaccine delivered by plasmid DNA and electroporation. We found that a strong poly-functional and poly-specific immune response was observed with high affinity neoantigens. Our pipeline - from the selection of neoantigens to vaccine design – was also applied to a new model of patient derived tumor xenograft resulting in therapeutic treatment.
These results suggest a feasible strategy for a neoantigen cancer vaccine that is simple and applicable for clinical developments.
Read the full article: https://doi.org/10.1186/s13046-019-1084-4